Neurobiology Research Unit (NRU) at Rigshospitalet has been the coordinating partner in the Center and the national partners have included the pharmaceutical company H. Lundbeck A/S and four academic partners: one from the University of Copenhagen and three from university hospitals in the Capital Region of Denmark. International partners included Massachusetts General Hospital/Harvard and the UK-based enterprise Imanova Ltd (acquired by Invicro LLC in August 2017). Additionally, Imperial College London has been involved in NeuroPharm as affiliated partner.
As illustrated in the organizational diagram below, the Center Director, Gitte Moos Knudsen, assisted by the full-time Center Manager, Peter Steen Jensen, has had the overall responsibility for meeting the milestones within NeuroPharm, including the financial and reporting responsibility.
The Center Director has been chair of the Center Steering Group which has had the function of reviewing the overall progress of the Center and discuss new strategic initiatives. The main task of the Steering Group was to assist and provide consultancy to the Director, for example in relation to major changes in the projects, meeting arrangements, and involvement of external experts.
Day-to-day basis operation of the Center was taken care of by a Council of Investigators (CoI) Group consisting of the younger work package leaders with the daily responsibility for the different NeuroPharm projects. The CoI group has been in charge of monitoring and discussing research progress in all projects by mutually informing about individual project status and discussing practical and scientific aspects.
